An in vitro binding assay for angiogenin using placental ribonuclease inhibitor.
A convenient in vitro assay for angiogenin has been developed which greatly facilitates its routine detection and quantitation. The assay is based on the capacity of angiogenin to bind placental ribonuclease inhibitor (PRI); it is less tedious and more versatile than existing procedures that measure blood vessel growth or cleavage of rRNA. The test sample is added to a reaction mixture containing a known quantity of PRI, which complexes any angiogenin present in the sample. A slight excess of RNase A, relative to PRI, is then added, and the amount of RNase A which remains unbound is determined by measuring the generation of acid-soluble fragments from yeast RNA. The assay is sensitive to 30 fmol of angiogenin and is linear over a 17-fold concentration range. Use of the binding assay in parallel with a conventional RNase A assay provides a means of detecting angiogenin in chromatographic fractions and differentiating it from RNases. This procedure makes possible the isolation of angiogenin from new sources, such as nonhuman sera. It may also be applicable to other biologically active proteins with sequence homology to RNase A, e.g., eosinophil cationic protein or eosinophil derived neurotoxin.
Bond
M D
MD
Center for Biochemical and Biophysical Sciences and Medicine, Harvard Medical School, Boston, Massachusetts 02115.
D000327:Adsorption; D006801:Humans; D066298:In Vitro Techniques; D009363:Neoplasm Proteins / Q000032:analysis* / Q000378:metabolism; D010926:Placental Hormones / Q000378:metabolism*; D012259:Ribonuclease, Pancreatic / Q000037:antagonists & inhibitors
D009363:Neoplasm Proteins; D010926:Placental Hormones; C022052:placental ribonuclease inhibitor; C046366:angiogenin; D012259:Ribonuclease, Pancreatic